Back to top
more

Biodesix (BDSX)

(Real Time Quote from BATS)

$0.44 USD

0.44
1,079,757

+0.02 (4.02%)

Updated Aug 6, 2025 12:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (73 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Avantor, Inc. (AVTR) Q2 Earnings Lag Estimates

by Zacks Equity Research

Avantor (AVTR) delivered earnings and revenue surprises of -4.00% and +0.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Biodesix (BDSX) delivered earnings and revenue surprises of 0% and 7.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sonida Senior Living (SNDA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sonida Senior Living (SNDA) delivered earnings and revenue surprises of 18.95% and 1.22%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

DocGo Inc. (DCGO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Motion Acquisition (DCGO) delivered earnings and revenue surprises of -800% and 0.90%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

GeneDx Holdings Corp. (WGS) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

GENEDX HOLDINGS (WGS) delivered earnings and revenue surprises of 154.55% and 9.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Revvity (RVTY) delivered earnings and revenue surprises of 5.21% and 0.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Avantor, Inc. (AVTR) Q1 Earnings Meet Estimates

by Zacks Equity Research

Avantor (AVTR) delivered earnings and revenue surprises of 0% and 1.72%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biodesix (BDSX) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Biodesix (BDSX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

BDSX Stock Rises After Publication of Study Data for Nodify CDT Test

by Zacks Equity Research

Biodesix announces positive study data for its Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal.

Zacks Equity Research

Biodesix (BDSX) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

The heavy selling pressure might have exhausted for Biodesix (BDSX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Biodesix, Inc. (BDSX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Biodesix (BDSX) delivered earnings and revenue surprises of 12.50% and 1.62%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Biodesix (BDSX) delivered earnings and revenue surprises of 11.11% and 11.68%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Organon (OGN) Surpasses Q2 Earnings Estimates

by Zacks Equity Research

Organon (OGN) delivered earnings and revenue surprises of 5.66% and 1.13%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Medpace (MEDP) Tops Q2 Earnings Estimates

by Zacks Equity Research

Medpace (MEDP) delivered earnings and revenue surprises of 9.13% and 0.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Sanghamitra Saha headshot

Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include CLEAR Secure (YOU), Applied DNA Sciences (APDN), Phreesia (PHR), Vigil Neuroscience (VIGL) and Biodesix (BDSX).

Zacks Equity Research

Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Biodesix (BDSX) delivered earnings and revenue surprises of 6.67% and 5.84%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Zacks Equity Research

Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Zacks Equity Research

Masimo (MASI) Gains Nearly 18% YTD: What's Driving the Rally?

by Zacks Equity Research

Masimo's (MASI) shares have risen year to date on the back of strong fundamentals. However, rising costs can be a cause of concern.

Zacks Equity Research

Reasons to Add Cencora (COR) Stock in Your Portfolio Now

by Zacks Equity Research

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Zacks Equity Research

Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Zacks Equity Research

Establishment Labs Holdings Inc. (ESTA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of 16.84% and 0.06%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Veradigm (MDRX) & MedAllies Partner for Better Care Decisions

by Zacks Equity Research

Veradigm's (MDRX) partnership with MedAllies is likely to gain access to a wider range of patient data and drive better treatment decisions.

Zacks Equity Research

Fresenius Medical (FMS) Divests Businesses to Optimize Portfolio

by Zacks Equity Research

Fresenius Medical (FMS) streamlines for success with three key divestments in 2023. These divestments are likely to impact operating income by EUR 500 million in the fourth quarter.

Zacks Equity Research

Here's Why You Should Hold UnitedHealth Group (UNH) Stock Now

by Zacks Equity Research

Improving membership levels, strategic acquisitions, expanding government business, improving operating margin and solid growth outlook poise UnitedHealth Group (UNH) well for growth.